Critical care interventions that preserve kidney function could transform outcomes for thousands of ICU patients facing potential dialysis. While severe metabolic acidosis traditionally signals poor prognosis, new evidence suggests targeted alkalinization therapy may offer a protective pathway. The BICARICU-2 trial examined sodium bicarbonate infusion in critically ill patients experiencing both severe metabolic acidemia and acute kidney injury. Though 90-day mortality rates remained statistically unchanged between treatment groups, patients receiving bicarbonate therapy demonstrated significantly lower rates of kidney replacement therapy initiation. This finding indicates that carefully administered alkalinization may help preserve residual kidney function during acute illness, potentially allowing organs to recover rather than requiring immediate dialysis intervention. The implications extend beyond immediate clinical outcomes. Avoiding kidney replacement therapy eliminates dialysis-related complications, reduces healthcare costs, and preserves quality of life. For patients whose kidneys retain some function, bicarbonate infusion appears to create conditions that support natural recovery processes. However, several limitations warrant consideration. The study focused specifically on critically ill populations with dual pathology, limiting generalizability to broader kidney injury scenarios. Additionally, while the therapy reduced dialysis initiation, long-term kidney function outcomes remain unclear. The mechanism likely involves correcting severe acid-base imbalances that can further damage compromised kidneys, though optimal dosing protocols require refinement. This represents incremental but meaningful progress in critical care nephrology, offering clinicians a potentially valuable tool for kidney preservation when traditional supportive measures prove insufficient.